Inviragen, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Private, Subsidiary
- Established
- 2003-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.inviragen.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)β’ Click on a phase to view related trials
Phase 1
2 (100.0%)Safety and Immunogenicity Study of an Inactivated Vaccine Against Hand, Foot and Mouth Disease Caused by Enterovirus 71
Phase 1
Completed
- Conditions
- Hand, Foot and Mouth Disease
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Inviragen Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01376479
- Locations
- πΈπ¬
Investigational Medicine Unit, National University Hospital, Singapore, Singapore
Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever
Phase 1
Completed
- Conditions
- Dengue Fever
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- Inviragen Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT01224639
- Locations
- π¨π΄
Program For The Study and Control of Tropical Diseases, Medellin, Colombia
News
No news found